Abiopharma

New Form 424B2 - BANK OF AMERICA CORP /DE/ <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001918704-26-023675 <b>Size:</b> 959 KB

New Form 424B2 - MORGAN STANLEY <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001839882-26-039791 <b>Size:</b> 354 KB

New Form 424B2 - TORONTO DOMINION BANK <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001140361-26-032719 <b>Size:</b> 423 KB

Announces Second Quarter 2026 Financial and Operating

New Form 424B2 - UBS AG <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001839882-26-039790 <b>Size:</b> 721 KB

New Form SCHEDULE 13G/A - KURA SUSHI USA, INC. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001193125-26-348404 <b>Size:</b> 1 MB

New Form 424B2 - Marex Group Ltd <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001104659-26-095676 <b>Size:</b> 723 KB

New Form SCHEDULE 13G/A - Elastic N.V. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001167557-26-000204 <b>Size:</b> 9 KB

Biofrontera BFRI Notification

New Form 424B2 - CITIGROUP INC <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0000950103-26-012303 <b>Size:</b> 229 KB

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

(30% Negative) DOGWOOD THERAPEUTICS, INC. (DWTX) Reports Q3 2026 Financial Results

New Form SCHEDULE 13G/A - Inhibikase Therapeutics, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001875620-26-000017 <b>Size:</b> 19 KB

New Form SCHEDULE 13G - MOLSON COORS BEVERAGE CO <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001167557-26-000202 <b>Size:</b> 8 KB

(99% Neutral) BED BATH & BEYOND, INC. (BBBY) Announces New Board Appointment